A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia

NCT02166814 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension, Dyslipidemia

Interventions

DRUG: Fimasartan and Rosuvastatin
DRUG: Fimasartan
DRUG: Rosuvastatin

Sponsor

Boryung Pharmaceutical Co., Ltd